Praxis Precision Medicines (PRAX)

Executive Summary

Praxis Precision Medicines is a public biotechnology company focused on developing precision therapies for central nervous system (CNS) disorders. The company's pipeline includes multiple late-stage candidates targeting essential tremor, epilepsy, and developmental and epileptic encephalopathies (DEE). Key programs: ulixacaltamide (Phase 3 for essential tremor), vormatrogine (Phase 3 for tonic-clonic epilepsy), and PRAX-562 (Phase 2/3 for SCN2A/SCN8A encephalopathy). With a market capitalization of approximately $9 billion, Praxis is advancing therapies that leverage genetic insights to address high unmet medical needs. The company's proprietary methodology aims to revolutionize neurology drug discovery, focusing on small molecules with precision mechanisms.

Upcoming Catalysts (preview)

• H2 2026Ulixacaltamide Phase 3 Essential Tremor Topline Data65% success
• H1 2026PRAX-628 Phase 2/3 Focal Seizure Topline Data60% success
• H1 2026PRAX-562 Phase 2/3 SCN2A/SCN8A Encephalopathy Update55% success